F3_M3

NTP Study Number:	C20303
Lock Date:	05/19/2008
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	3.0.2.0_001
PWG Approval Date:	07/01/2011

HISTORICAL CONTROL STUDIES
From June 2013 report

SAME ROUTE
20011-06 -- 1-Bromopropane (INHALATION AIR)
60311-06 -- Cobalt (INHALATION AIR)
99017-06 -- Diethylamine (INHALATION AIR)
20515-04 -- Metal working fluids (CIMSTAR 3800) (INHALATION AIR)
93025-06 -- Tetralin (INHALATION AIR)

ALL ROUTES
99037-06 -- alpha/beta Thujone mixture (GAVAGE METHYLCELLULOSE)
20011-06 -- 1-Bromopropane (INHALATION AIR)
60311-06 -- Cobalt (INHALATION AIR)
99017-06 -- Diethylamine (INHALATION AIR)
99031-04 -- Ginkgo biloba extract (GAVAGE CORN OIL)
20005-06 -- Ginseng (GAVAGE WATER)
20203-04 -- Green tea extract (GAVAGE WATER)
20006-04 -- Indole-3-carbinol (GAVAGE CORN OIL)
20007-06 -- Kava kava extract (GAVAGE CORN OIL)
20515-04 -- Metal working fluids (CIMSTAR 3800) (INHALATION AIR)
95003-06 -- Methyl trans-styryl ketone (SKIN ETHANOL)
20107-04 -- N,N-Dimethyl-p-toluidine (GAVAGE CORN OIL)
20009-04 -- beta-Picoline (ORAL WATER)
99032-04 -- Pyrogallol (SKIN ETHANOL)
20320-04 -- Tetrabromobisphenol A (GAVAGE CORN OIL)
93025-06 -- Tetralin (INHALATION AIR)
88133-08 -- Trimethylolpropane triacrylate (SKIN ACETONE)
96014-06 -- Water disinfection byproducts (Bromodichloroacetic acid) (ORAL WATER)

FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.

Adrenal Cortex
Adrenal Medulla
Bone Marrow
Islets, Pancreatic
Kidney
Liver
Lung
Ovary
Pituitary Gland
Spleen
Testes
Thyroid Gland

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF VINYLIDENE CHLORIDE

MALE MICE

Organ	Morphology
Intestine Small: Duodenum	Carcinoma
Kidney: Renal Tubule	Adenoma
	Carcinoma
	Carcinoma or Adenoma
Liver	Hepatocellular Adenoma
	Hepatocellular Carcinoma
	Hepatocellular Carcinoma or Hepatoblastoma
All Organs	Hemangiosarcoma or Hemangioma
	Benign Tumors
	Malignant Tumors

FEMALE MICE

Organ	Morphology
Harderian Gland	Adenoma
Liver	Hemangiosarcoma
	Hepatocellular Adenoma
	Hepatocellular Carcinoma
	Hepatocellular Carcinoma or Hepatoblastoma
	Hepatocellular Carcinoma or Hepatocellular Adenoma
	Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung	Alveolar/Bronchiolar Carcinoma
Skin	Fibrous Histiocytoma
Stomach, Forestomach	Squamous Cell Papilloma
All Organs	Hemangiosarcoma
	Hemangiosarcoma or Hemangioma
	Malignant Tumors

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Adrenal Cortex Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	4/50 (8%)	2/50 (4%)
POLY-3 RATE (b)	1/42.11	1/47.23	4/41.50	2/36.57
POLY-3 PERCENT (g)	2.4%	2.1%	9.6%	5.5%
TERMINAL (d)	1/29 (3%)	1/40 (3%)	4/32 (13%)	1/19 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	705
HC TUMORS SAME ROUTE	22/247 (9%)			
HC TUMORS ALL ROUTES	56/895 (6%)			
STATISTICAL TESTS				
POLY 3	P=0.218	P=0.734N	P=0.173	P=0.451
POLY 1.5	P=0.258	P=0.745N	P=0.175	P=0.473
POLY 6	P=0.170	P=0.720N	P=0.174	P=0.418
COCH-ARM / FISHERS	P=0.313	P=0.753N	P=0.181	P=0.500
MAX-ISO-POLY-3	P=0.247	P=0.468N	P=0.081	P=0.254
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	P=0.738	P=1.000	P=0.402	P=1.000
CURR VS HC SAME RTE	P=0.161			
CURR VS HC ALL RTES	P=0.252			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Adrenal Medulla				
Pheochromocytoma: Benign, Complex, Malignant, NOS				
TUMOR RATES				
OVERALL (a)	2/50 (4%)	1/50 (2%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	2/42.11	1/47.49	0/41.50	1/36.58
POLY-3 PERCENT (g)	4.8%	2.1%	0%	2.7%
TERMINAL (d)	2/29 (7%)	0/40 (0%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	729 (T)	658	---	701
HC TUMORS SAME ROUTE	3/245 (1%)			
HC TUMORS ALL ROUTES	4/890 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.386N	P=0.458N	P=0.240N	P=0.549N
POLY 1.5	P=0.379N	P=0.476N	P=0.240N	P=0.527N
POLY 6	P=0.390N	P=0.436N	P=0.239N	P=0.581N
COCH-ARM / FISHERS	P=0.366N	P=0.500N	P=0.247N	P=0.500N
MAX-ISO-POLY-3	P=0.295N	P=0.258N	P=0.079N	P=0.333N
HISTCONT SAME RTE	P=0.331	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.097	P=0.251	P=1.000	P=0.200
CURR VS HC SAME RTE	P=0.081			
CURR VS HC ALL RTES	P=0.002**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Bone Marrow				
Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	0/50 (0%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.56	0/47.23	1/41.50	2/37.16
POLY-3 PERCENT (g)	2.4%	0%	2.4%	5.4%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	1/32 (3%)	0/19 (0%)
FIRST INCIDENCE	596	---	729 (T)	548
HC TUMORS SAME ROUTE	3/248 (1%)			
HC TUMORS ALL ROUTES	10/898 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.204	P=0.479N	P=0.755	P=0.453
POLY 1.5	P=0.222	P=0.488N	P=0.757	P=0.474
POLY 6	P=0.183	P=0.469N	P=0.755	P=0.421
COCH-ARM / FISHERS	P=0.247	P=0.500N	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.207	P=0.158N	P=0.492	P=0.255
HISTCONT SAME RTE	P=0.122	P=1.000	P=1.000	P=0.144
HISTCONT ALL RTES	P=0.073	P=1.000	P=1.000	P=0.059
CURR VS HC SAME RTE	P=0.708			
CURR VS HC ALL RTES	P=0.565			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	7/50 (14%)	6/50 (12%)	8/50 (16%)	8/50 (16%)
POLY-3 RATE (b)	7/42.35	6/47.23	8/42.26	8/37.68
POLY-3 PERCENT (g)	16.5%	12.7%	18.9%	21.2%
TERMINAL (d)	5/29 (17%)	6/40 (15%)	5/32 (16%)	4/19 (21%)
FIRST INCIDENCE	694	729 (T)	599	575
HC TUMORS SAME ROUTE	26/250 (10%)			
HC TUMORS ALL ROUTES	112/900 (12%)			
STATISTICAL TESTS				
POLY 3	P=0.252	P=0.416N	P=0.498	P=0.401
POLY 1.5	P=0.305	P=0.451N	P=0.496	P=0.446
POLY 6	P=0.194	P=0.376N	P=0.509	P=0.338
COCH-ARM / FISHERS	P=0.380	P=0.500N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.376	P=0.314N	P=0.385	P=0.305
HISTCONT SAME RTE	P=0.033*	P=1.000	P=0.092	P=0.064
HISTCONT ALL RTES	P=0.117	P=1.000	P=0.200	P=0.117
CURR VS HC SAME RTE	P=0.373			
CURR VS HC ALL RTES	P=0.676			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Harderian Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/42.11	2/47.42	1/41.50	0/36.47
POLY-3 PERCENT (g)	0%	4.2%	2.4%	0%
TERMINAL (d)	0/29 (0%)	1/40 (3%)	1/32 (3%)	0/19 (0%)
FIRST INCIDENCE	---	680	729 (T)	---
HC TUMORS SAME ROUTE	17/250 (7%)			
HC TUMORS ALL ROUTES	34/900 (4%)			
STATISTICAL TESTS				
POLY 3	P=0.504N	P=0.265	P=0.497	(e)
POLY 1.5	P=0.484N	P=0.253	P=0.498	(e)
POLY 6	P=0.533N	P=0.280	P=0.498	(e)
COCH-ARM / FISHERS	P=0.461N	P=0.247	P=0.500	(e)
MAX-ISO-POLY-3	P=0.382	P=0.102	P=0.158	(e)
HISTCONT SAME RTE	(h)	(h)	(h)	(e)
HISTCONT ALL RTES	(h)	(h)	(h)	(e)
CURR VS HC SAME RTE	P=0.054			
CURR VS HC ALL RTES	P=0.175			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Harderian Gland				
Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	7/50 (14%)	8/50 (16%)	9/50 (18%)	8/50 (16%)
POLY-3 RATE (b)	7/42.35	8/47.42	9/42.26	8/37.68
POLY-3 PERCENT (g)	16.5%	16.9%	21.3%	21.2%
TERMINAL (d)	5/29 (17%)	7/40 (18%)	6/32 (19%)	4/19 (21%)
FIRST INCIDENCE	694	680	599	575
HC TUMORS SAME ROUTE	43/250 (17%)			
HC TUMORS ALL ROUTES	146/900 (16%)			
STATISTICAL TESTS				
POLY 3	P=0.302	P=0.594	P=0.389	P=0.401
POLY 1.5	P=0.364	P=0.555	P=0.387	P=0.446
POLY 6	P=0.231	P=0.582N	P=0.399	P=0.338
COCH-ARM / FISHERS	P=0.448	P=0.500	P=0.393	P=0.500
MAX-ISO-POLY-3	P=0.484	P=0.483	P=0.288	P=0.305
HISTCONT SAME RTE	P=0.542	P=1.000	P=0.416	P=0.438
HISTCONT ALL RTES	P=0.454	P=1.000	P=0.341	P=0.377
CURR VS HC SAME RTE	P=0.717			
CURR VS HC ALL RTES	P=0.765			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Duodenum				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.11	0/47.23	0/41.50	2/37.01
POLY-3 PERCENT (g)	0%	0%	0%	5.4%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	0/32 (0%)	1/19 (5%)
FIRST INCIDENCE	---	---	---	563
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	1/900 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.038*	(e)	(e)	P=0.209
POLY 1.5	P=0.041*	(e)	(e)	P=0.222
POLY 6	P=0.035*	(e)	(e)	P=0.192
COCH-ARM / FISHERS	P=0.046*	(e)	(e)	P=0.247
MAX-ISO-POLY-3	P=0.032*	(e)	(e)	P=0.075
HISTCONT SAME RTE	P=0.022*	(e)	(e)	P=0.027*
HISTCONT ALL RTES	P<0.001**	(e)	(e)	P<0.001**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.547			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Ileum				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.11	1/47.23	0/41.50	0/36.47
POLY-3 PERCENT (g)	0%	2.1%	0%	0%
TERMINAL (d)	0/29 (0%)	1/40 (3%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/900 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Jejunum				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.11	2/47.23	0/41.50	0/36.47
POLY-3 PERCENT (g)	0%	4.2%	0%	0%
TERMINAL (d)	0/29 (0%)	2/40 (5%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	---	729 (T)	---	---
HC TUMORS SAME ROUTE	6/250 (2%)			
HC TUMORS ALL ROUTES	18/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.415N	P=0.264	(e)	(e)
POLY 1.5	P=0.409N	P=0.253	(e)	(e)
POLY 6	P=0.422N	P=0.278	(e)	(e)
COCH-ARM / FISHERS	P=0.405N	P=0.247	(e)	(e)
MAX-ISO-POLY-3	P=0.331N	P=0.101	(e)	(e)
HISTCONT SAME RTE	P=1.000	P=0.457	(e)	(e)
HISTCONT ALL RTES	P=1.000	P=0.317	(e)	(e)
CURR VS HC SAME RTE	P=0.380			
CURR VS HC ALL RTES	P=0.352			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Site Unspecified				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	3/50 (6%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/42.11	3/47.23	0/41.50	2/37.01
POLY-3 PERCENT (g)	0%	6.4%	0%	5.4%
TERMINAL (d)	0/29 (0%)	3/40 (8%)	0/32 (0%)	1/19 (5%)
FIRST INCIDENCE	---	729 (T)	---	563
HC TUMORS SAME ROUTE	6/250 (2%)			
HC TUMORS ALL ROUTES	19/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.311	P=0.141	(e)	P=0.209
POLY 1.5	P=0.329	P=0.131	(e)	P=0.222
POLY 6	P=0.288	P=0.153	(e)	P=0.192
COCH-ARM / FISHERS	P=0.351	P=0.121	(e)	P=0.247
MAX-ISO-POLY-3	P=0.156	P=0.057	(e)	P=0.075
HISTCONT SAME RTE	P=0.483	P=0.225	(e)	P=0.373
HISTCONT ALL RTES	P=0.329	P=0.065	(e)	P=0.244
CURR VS HC SAME RTE	P=0.380			
CURR VS HC ALL RTES	P=0.336			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Site Unspecified				
Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	3/50 (6%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.11	3/47.23	1/41.50	2/37.01
POLY-3 PERCENT (g)	2.4%	6.4%	2.4%	5.4%
TERMINAL (d)	1/29 (3%)	3/40 (8%)	1/32 (3%)	1/19 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	563
HC TUMORS SAME ROUTE	9/250 (4%)			
HC TUMORS ALL ROUTES	30/900 (3%)			
STATISTICAL TESTS				
POLY 3	P=0.463	P=0.348	P=0.758	P=0.455
POLY 1.5	P=0.491	P=0.330	P=0.758	P=0.476
POLY 6	P=0.424	P=0.370	P=0.759	P=0.425
COCH-ARM / FISHERS	P=0.526	P=0.309	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.436	P=0.197	P=0.495	P=0.256
HISTCONT SAME RTE	P=0.586	P=0.335	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.542	P=0.234	P=1.000	P=0.474
CURR VS HC SAME RTE	P=0.640			
CURR VS HC ALL RTES	P=0.636			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Islets, Pancreatic Adenoma				
TUMOR RATES				
OVERALL (a)	2/50 (4%)	1/49 (2%)	1/49 (2%)	0/49 (0%)
POLY-3 RATE (b)	2/42.53	1/46.55	1/41.59	0/35.58
POLY-3 PERCENT (g)	4.7%	2.2%	2.4%	0%
TERMINAL (d)	1/29 (3%)	1/40 (3%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	610	729 (T)	648	---
HC TUMORS SAME ROUTE	6/246 (2%)			
HC TUMORS ALL ROUTES	19/895 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.186N	P=0.469N	P=0.508N	P=0.278N
POLY 1.5	P=0.173N	P=0.484N	P=0.508N	P=0.261N
POLY 6	P=0.201N	P=0.449N	P=0.505N	P=0.306N
COCH-ARM / FISHERS	P=0.156N	P=0.508N	P=0.508N	P=0.253N
MAX-ISO-POLY-3	P=0.184N	P=0.264N	P=0.288N	P=0.114N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	(h)	(h)	(h)	(h)
CURR VS HC SAME RTE	P=0.514			
CURR VS HC ALL RTES	P=0.371			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Kidney: Renal Tubule Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	5/50 (10%)	19/50 (38%)	10/50 (20%)
POLY-3 RATE (b)	0/42.11	5/47.23	19/43.00	10/37.48
POLY-3 PERCENT (g)	0%	10.6%	44.2%	26.7%
TERMINAL (d)	0/29 (0%)	5/40 (13%)	15/32 (47%)	8/19 (42%)
FIRST INCIDENCE	---	729 (T)	600	525
HC TUMORS SAME ROUTE	0/248 (0%)			
HC TUMORS ALL ROUTES	8/894 (1%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.041*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.037*	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.048*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P=0.002**	P=0.028*	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.019*	P<0.001**	P<0.001**
HISTCONT SAME RTE	P=0.004**	P=0.004**	P<0.001**	P=0.003**
HISTCONT ALL RTES	P<0.001**	P<0.001**	P<0.001**	P<0.001**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.577			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Kidney: Renal Tubule Carcinoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	7/50 (14%)	31/50 (62%)	18/50 (36%)
POLY-3 RATE (b)	0/42.11	7/47.66	31/43.95	18/39.28
POLY-3 PERCENT (g)	0%	14.7%	70.5%	45.8%
TERMINAL (d)	0/29 (0%)	5/40 (13%)	24/32 (75%)	10/19 (53%)
FIRST INCIDENCE	---	619	429	537
HC TUMORS SAME ROUTE	0/248 (0%)			
HC TUMORS ALL ROUTES	3/894 (0%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P=0.012*	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P=0.010**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P=0.016*	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P=0.006**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P=0.006**	P<0.001**	P<0.001**
HISTCONT SAME RTE	P<0.001**	P=0.002**	P<0.001**	P<0.001**
HISTCONT ALL RTES	P<0.001**	P<0.001**	P<0.001**	P<0.001**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.569			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Kidney: Renal Tubule Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	11/50 (22%)	37/50 (74%)	27/50 (54%)
POLY-3 RATE (b)	0/42.11	11/47.66	37/45.16	27/40.29
POLY-3 PERCENT (g)	0%	23.1%	81.9%	67%
TERMINAL (d)	0/29 (0%)	9/40 (23%)	27/32 (84%)	17/19 (90%)
FIRST INCIDENCE	---	619	429	525
HC TUMORS SAME ROUTE	0/248 (0%)			
HC TUMORS ALL ROUTES	11/894 (1%)			
STATISTICAL TESTS				
POLY 3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	P<0.001**	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	P<0.001**	P<0.001**	P<0.001**
MAX-ISO-POLY-3	P<0.001**	P<0.001**	P<0.001**	P<0.001**
HISTCONT SAME RTE	P<0.001**	P<0.001**	P<0.001**	P<0.001**
HISTCONT ALL RTES	P<0.001**	P<0.001**	P<0.001**	P<0.001**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.469			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hemangioma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	0/42.11	1/47.23	2/41.51	0/36.47
POLY-3 PERCENT (g)	0%	2.1%	4.8%	0%
TERMINAL (d)	0/29 (0%)	1/40 (3%)	1/32 (3%)	0/19 (0%)
FIRST INCIDENCE	---	729 (T)	726	---
HC TUMORS SAME ROUTE	0/249 (0%)			
HC TUMORS ALL ROUTES	4/899 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.600	P=0.523	P=0.234	(e)
POLY 1.5	P=0.642	P=0.513	P=0.234	(e)
POLY 6	P=0.534	P=0.534	P=0.235	(e)
COCH-ARM / FISHERS	P=0.616N	P=0.500	P=0.247	(e)
MAX-ISO-POLY-3	P=0.357	P=0.186	P=0.076	(e)
HISTCONT SAME RTE	P=0.240	P=0.125	P=0.023*	(e)
HISTCONT ALL RTES	P=0.260	P=0.317	P=0.012*	(e)
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.574			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	2/50 (4%)	2/50 (4%)	3/50 (6%)	3/50 (6%)
POLY-3 RATE (b)	2/42.94	2/47.23	3/41.50	3/37.92
POLY-3 PERCENT (g)	4.7%	4.2%	7.2%	7.9%
TERMINAL (d)	0/29 (0%)	2/40 (5%)	3/32 (9%)	0/19 (0%)
FIRST INCIDENCE	596	729 (T)	729 (T)	470
HC TUMORS SAME ROUTE	8/249 (3%)			
HC TUMORS ALL ROUTES	54/899 (6%)			
STATISTICAL TESTS				
POLY 3	P=0.292	P=0.659N	P=0.484	P=0.443
POLY 1.5	P=0.327	P=0.673N	P=0.490	P=0.470
POLY 6	P=0.247	P=0.642N	P=0.480	P=0.404
COCH-ARM / FISHERS	P=0.371	P=0.691N	P=0.500	P=0.500
MAX-ISO-POLY-3	P=0.439	P=0.462N	P=0.313	P=0.286
HISTCONT SAME RTE	P=0.111	P=1.000	P=0.221	P=0.192
HISTCONT ALL RTES	P=0.689	P=1.000	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.745			
CURR VS HC ALL RTES	P=0.582			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Adenoma				
TUMOR RATES				
OVERALL (a)	37/50 (74%)	35/50 (70%)	33/50 (66%)	25/50 (50%)
POLY-3 RATE (b)	37/47.67	35/48.30	33/44.74	25/41.66
POLY-3 PERCENT (g)	77.6%	72.5%	73.8%	60%
TERMINAL (d)	21/29 (72%)	31/40 (78%)	25/32 (78%)	12/19 (63%)
FIRST INCIDENCE	443	619	429	471
HC TUMORS SAME ROUTE	143/249 (57%)			
HC TUMORS ALL ROUTES	557/899 (62%)			
STATISTICAL TESTS				
POLY 3	P=0.040N*	P=0.361N	P=0.422N	P=0.046N*
POLY 1.5	P=0.016N*	P=0.380N	P=0.350N	P=0.023N*
POLY 6	P=0.114N	P=0.347N	P=0.510N	P=0.111N
COCH-ARM / FISHERS	P=0.005N**	P=0.412N	P=0.257N	P=0.011N*
MAX-ISO-POLY-3	P=0.056N	P=0.277N	P=0.330N	P=0.034N*
HISTCONT SAME RTE	P=0.365	P=0.074	P=0.068	P=1.000
HISTCONT ALL RTES	P=0.710	P=0.274	P=0.233	P=1.000
CURR VS HC SAME RTE	P=0.027*			
CURR VS HC ALL RTES	P=0.124			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma				
TUMOR RATES				
OVERALL (a)	26/50 (52%)	19/50 (38%)	15/50 (30%)	29/50 (58%)
POLY-3 RATE (b)	26/47.30	19/49.85	15/45.17	29/45.04
POLY-3 PERCENT (g)	55%	38.1%	33.2%	64.4%
TERMINAL (d)	11/29 (38%)	11/40 (28%)	7/32 (22%)	10/19 (53%)
FIRST INCIDENCE	443	521	508	425
HC TUMORS SAME ROUTE	82/249 (33%)			
HC TUMORS ALL ROUTES	322/899 (36%)			
STATISTICAL TESTS				
POLY 3	P=0.118	P=0.070N	P=0.026N*	P=0.234
POLY 1.5	P=0.153	P=0.086N	P=0.023N*	P=0.283
POLY 6	P=0.080	P=0.056N	P=0.029N*	P=0.168
COCH-ARM / FISHERS	P=0.214	P=0.114N	P=0.021N*	P=0.344
MAX-ISO-POLY-3	P=0.024*	P=0.050N*	P=0.017N*	P=0.178
HISTCONT SAME RTE	P=0.034*	P=0.393	P=1.000	P=0.018*
HISTCONT ALL RTES	P=0.042*	P=1.000	P=1.000	P=0.005**
CURR VS HC SAME RTE	P=0.022*			
CURR VS HC ALL RTES	P=0.029*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	27/50 (54%)	19/50 (38%)	15/50 (30%)	29/50 (58%)
POLY-3 RATE (b)	27/47.30	19/49.85	15/45.17	29/45.04
POLY-3 PERCENT (g)	57.1%	38.1%	33.2%	64.4%
TERMINAL (d)	12/29 (41%)	11/40 (28%)	7/32 (22%)	10/19 (53%)
FIRST INCIDENCE	443	521	508	425
HC TUMORS SAME ROUTE	85/249 (34%)			
HC TUMORS ALL ROUTES	344/899 (38%)			
STATISTICAL TESTS				
POLY 3	P=0.156	P=0.045N*	P=0.015N*	P=0.302
POLY 1.5	P=0.198	P=0.057N	P=0.014N*	P=0.357
POLY 6	P=0.110	P=0.035N*	P=0.017N*	P=0.227
COCH-ARM / FISHERS	P=0.266	P=0.080N	P=0.013N*	P=0.420
MAX-ISO-POLY-3	P=0.028*	P=0.032N*	P=0.010N**	P=0.237
HISTCONT SAME RTE	P=0.052	P=0.453	P=1.000	P=0.025*
HISTCONT ALL RTES	P=0.069	P=1.000	P=1.000	P=0.010**
CURR VS HC SAME RTE	P=0.022*			
CURR VS HC ALL RTES	P=0.034*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma or Hepatocellular Adenoma				
TUMOR RATES				
OVERALL (a)	44/50 (88%)	41/50 (82%)	41/50 (82%)	42/50 (84%)
POLY-3 RATE (b)	44/49.33	41/49.96	41/47.22	42/47.06
POLY-3 PERCENT (g)	89.2%	82.1%	86.8%	89.2%
TERMINAL (d)	24/29 (83%)	32/40 (80%)	28/32 (88%)	17/19 (90%)
FIRST INCIDENCE	443	521	429	425
HC TUMORS SAME ROUTE	185/249 (74%)			
HC TUMORS ALL ROUTES	698/899 (78%)			
STATISTICAL TESTS				
POLY 3	P=0.425	P=0.233N	P=0.481N	P=0.634
POLY 1.5	P=0.552	P=0.252N	P=0.400N	P=0.520N
POLY 6	P=0.270	P=0.219N	P=0.575N	P=0.482
COCH-ARM / FISHERS	P=0.397N	P=0.288N	P=0.288N	P=0.387N
MAX-ISO-POLY-3	P=0.475	P=0.157N	P=0.356N	P=0.496
HISTCONT SAME RTE	P=0.022*	P=0.184	P=0.065	P=0.039*
HISTCONT ALL RTES	P=0.110	P=1.000	P=0.209	P=0.110
CURR VS HC SAME RTE	P=0.038*			
CURR VS HC ALL RTES	P=0.142			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	45/50 (90%)	41/50 (82%)	41/50 (82%)	42/50 (84%)
POLY-3 RATE (b)	45/49.33	41/49.96	41/47.22	42/47.06
POLY-3 PERCENT (g)	91.2%	82.1%	86.8%	89.2%
TERMINAL (d)	25/29 (86%)	32/40 (80%)	28/32 (88%)	17/19 (90%)
FIRST INCIDENCE	443	521	429	425
HC TUMORS SAME ROUTE	186/249 (75%)			
HC TUMORS ALL ROUTES	701/899 (78%)			
STATISTICAL TESTS				
POLY 3	P=0.529	P=0.146N	P=0.350N	P=0.506N
POLY 1.5	P=0.461N	P=0.162N	P=0.279N	P=0.389N
POLY 6	P=0.362	P=0.134N	P=0.442N	P=0.632
COCH-ARM / FISHERS	P=0.310N	P=0.194N	P=0.194N	P=0.277N
MAX-ISO-POLY-3	P=0.347N	P=0.090N	P=0.239N	P=0.363N
HISTCONT SAME RTE	P=0.024*	P=0.205	P=0.072	P=0.043*
HISTCONT ALL RTES	P=0.123	P=1.000	P=0.223	P=0.118
CURR VS HC SAME RTE	P=0.021*			
CURR VS HC ALL RTES	P=0.068			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocholangiocarcinoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	1/42.21	2/47.34	2/42.63	3/37.41
POLY-3 PERCENT (g)	2.4%	4.2%	4.7%	8%
TERMINAL (d)	0/29 (0%)	1/40 (3%)	0/32 (0%)	1/19 (5%)
FIRST INCIDENCE	704	701	429	563
HC TUMORS SAME ROUTE	1/249 (0%)			
HC TUMORS ALL ROUTES	9/899 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.181	P=0.540	P=0.503	P=0.262
POLY 1.5	P=0.203	P=0.523	P=0.501	P=0.282
POLY 6	P=0.155	P=0.560	P=0.509	P=0.236
COCH-ARM / FISHERS	P=0.232	P=0.500	P=0.500	P=0.309
MAX-ISO-POLY-3	P=0.226	P=0.324	P=0.284	P=0.139
HISTCONT SAME RTE	P=0.006**	P=0.045*	P=0.046*	P=0.019*
HISTCONT ALL RTES	P=0.003**	P=0.134	P=0.119	P=0.013*
CURR VS HC SAME RTE	P=0.090			
CURR VS HC ALL RTES	P=0.504			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Lung				
Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	7/50 (14%)	8/50 (16%)	8/50 (16%)	7/50 (14%)
POLY-3 RATE (b)	7/42.25	8/47.49	8/43.45	7/37.16
POLY-3 PERCENT (g)	16.6%	16.9%	18.4%	18.8%
TERMINAL (d)	6/29 (21%)	7/40 (18%)	5/32 (16%)	5/19 (26%)
FIRST INCIDENCE	694	658	404	548
HC TUMORS SAME ROUTE	32/250 (13%)			
HC TUMORS ALL ROUTES	138/900 (15%)			
STATISTICAL TESTS				
POLY 3	P=0.430	P=0.597	P=0.524	P=0.512
POLY 1.5	P=0.496	P=0.557	P=0.513	P=0.560
POLY 6	P=0.346	P=0.576N	P=0.540	P=0.440
COCH-ARM / FISHERS	P=0.527N	P=0.500	P=0.500	P=0.613N
MAX-ISO-POLY-3	P=0.630	P=0.486	P=0.410	P=0.399
HISTCONT SAME RTE	P=0.162	P=0.334	P=0.229	P=0.241
HISTCONT ALL RTES	P=0.707	P=1.000	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.665			
CURR VS HC ALL RTES	P=0.876			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Lung				
Alveolar/Bronchiolar Carcinoma				
TUMOR RATES				
OVERALL (a)	9/50 (18%)	9/50 (18%)	8/50 (16%)	6/50 (12%)
POLY-3 RATE (b)	9/42.76	9/47.47	8/42.92	6/36.82
POLY-3 PERCENT (g)	21.1%	19%	18.6%	16.3%
TERMINAL (d)	8/29 (28%)	8/40 (20%)	5/32 (16%)	5/19 (26%)
FIRST INCIDENCE	512	664	508	633
HC TUMORS SAME ROUTE	50/250 (20%)			
HC TUMORS ALL ROUTES	123/900 (14%)			
STATISTICAL TESTS				
POLY 3	P=0.350N	P=0.506N	P=0.497N	P=0.400N
POLY 1.5	P=0.289N	P=0.547N	P=0.502N	P=0.347N
POLY 6	P=0.431N	P=0.454N	P=0.479N	P=0.482N
COCH-ARM / FISHERS	P=0.217N	P=0.602N	P=0.500N	P=0.288N
MAX-ISO-POLY-3	P=0.500N	P=0.405N	P=0.388N	P=0.307N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	P=0.580	P=0.330	P=0.371	P=1.000
CURR VS HC SAME RTE	P=0.933			
CURR VS HC ALL RTES	P=0.349			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Lung				
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	13/50 (26%)	16/50 (32%)	14/50 (28%)	12/50 (24%)
POLY-3 RATE (b)	13/42.90	16/47.74	14/44.55	12/37.50
POLY-3 PERCENT (g)	30.3%	33.5%	31.4%	32%
TERMINAL (d)	11/29 (38%)	14/40 (35%)	9/32 (28%)	9/19 (47%)
FIRST INCIDENCE	512	658	404	548
HC TUMORS SAME ROUTE	77/250 (31%)			
HC TUMORS ALL ROUTES	250/900 (28%)			
STATISTICAL TESTS				
POLY 3	P=0.513	P=0.459	P=0.547	P=0.531
POLY 1.5	P=0.478N	P=0.403	P=0.526	P=0.587N
POLY 6	P=0.393	P=0.534	P=0.580	P=0.425
COCH-ARM / FISHERS	P=0.364N	P=0.330	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.661	P=0.376	P=0.454	P=0.436
HISTCONT SAME RTE	P=1.000	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.701	P=0.381	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.740			
CURR VS HC ALL RTES	P=0.905			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Mammary Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.11	0/47.23	0/41.50	0/36.47
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/900 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Pituitary Gland: Pars Distalis or Unspecified Site				
Adenoma				
TUMOR RATES				
OVERALL (a)	0/49 (0%)	0/49 (0%)	0/50 (0%)	0/46 (0%)
POLY-3 RATE (b)	0/41.44	0/46.42	0/41.50	0/33.23
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	0/32 (0%)	0/18 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	1/243 (0%)			
HC TUMORS ALL ROUTES	3/884 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Pituitary Gland: Pars Distalis or Unspecified Site				
Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/49 (0%)	0/49 (0%)	0/50 (0%)	0/46 (0%)
POLY-3 RATE (b)	0/41.44	0/46.42	0/41.50	0/33.23
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	0/32 (0%)	0/18 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	1/243 (0%)			
HC TUMORS ALL ROUTES	3/884 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.11	2/47.23	1/41.50	2/36.47
POLY-3 PERCENT (g)	2.4%	4.2%	2.4%	5.5%
TERMINAL (d)	1/29 (3%)	2/40 (5%)	1/32 (3%)	2/19 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	10/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.380	P=0.540	P=0.758	P=0.450
POLY 1.5	P=0.408	P=0.523	P=0.758	P=0.473
POLY 6	P=0.343	P=0.560	P=0.759	P=0.416
COCH-ARM / FISHERS	P=0.444	P=0.500	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.409	P=0.324	P=0.495	P=0.254
HISTCONT SAME RTE	P=0.089	P=0.180	P=1.000	P=0.141
HISTCONT ALL RTES	P=0.007**	P=0.045*	P=1.000	P=0.029*
CURR VS HC SAME RTE	P=0.706			
CURR VS HC ALL RTES	P=0.555			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.11	2/47.23	1/41.50	2/36.47
POLY-3 PERCENT (g)	2.4%	4.2%	2.4%	5.5%
TERMINAL (d)	1/29 (3%)	2/40 (5%)	1/32 (3%)	2/19 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	10/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.380	P=0.540	P=0.758	P=0.450
POLY 1.5	P=0.408	P=0.523	P=0.758	P=0.473
POLY 6	P=0.343	P=0.560	P=0.759	P=0.416
COCH-ARM / FISHERS	P=0.444	P=0.500	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.409	P=0.324	P=0.495	P=0.254
HISTCONT SAME RTE	P=0.089	P=0.180	P=1.000	P=0.141
HISTCONT ALL RTES	P=0.007**	P=0.045*	P=1.000	P=0.029*
CURR VS HC SAME RTE	P=0.706			
CURR VS HC ALL RTES	P=0.555			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	1/42.11	2/47.23	1/41.50	2/36.47
POLY-3 PERCENT (g)	2.4%	4.2%	2.4%	5.5%
TERMINAL (d)	1/29 (3%)	2/40 (5%)	1/32 (3%)	2/19 (11%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	729 (T)
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	4/900 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.380	P=0.540	P=0.758	P=0.450
POLY 1.5	P=0.408	P=0.523	P=0.758	P=0.473
POLY 6	P=0.343	P=0.560	P=0.759	P=0.416
COCH-ARM / FISHERS	P=0.444	P=0.500	P=0.753N	P=0.500
MAX-ISO-POLY-3	P=0.409	P=0.324	P=0.495	P=0.254
HISTCONT SAME RTE	P=0.022*	P=0.045*	P=0.306	P=0.048*
HISTCONT ALL RTES	P<0.001**	P=0.002**	P=0.225	P=0.003**
CURR VS HC SAME RTE	P=0.086			
CURR VS HC ALL RTES	P=0.134			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/42.11	0/47.23	0/41.50	0/36.47
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	3/900 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Spleen				
Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	2/50 (4%)	3/49 (6%)	1/50 (2%)	4/50 (8%)
POLY-3 RATE (b)	2/42.94	3/46.55	1/41.80	4/37.16
POLY-3 PERCENT (g)	4.7%	6.5%	2.4%	10.8%
TERMINAL (d)	0/29 (0%)	3/40 (8%)	0/32 (0%)	2/19 (11%)
FIRST INCIDENCE	596	729 (T)	648	548
HC TUMORS SAME ROUTE	9/247 (4%)			
HC TUMORS ALL ROUTES	31/888 (4%)			
STATISTICAL TESTS				
POLY 3	P=0.236	P=0.537	P=0.509N	P=0.272
POLY 1.5	P=0.261	P=0.518	P=0.507N	P=0.301
POLY 6	P=0.207	P=0.559	P=0.510N	P=0.232
COCH-ARM / FISHERS	P=0.295	P=0.490	P=0.500N	P=0.339
MAX-ISO-POLY-3	P=0.233	P=0.363	P=0.291N	P=0.168
HISTCONT SAME RTE	P=0.113	P=0.310	P=1.000	P=0.074
HISTCONT ALL RTES	P=0.054	P=0.236	P=1.000	P=0.018*
CURR VS HC SAME RTE	P=0.861			
CURR VS HC ALL RTES	P=0.833			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Stomach, Forestomach **Squamous Cell Papilloma**				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	1/42.11	0/47.23	0/41.50	1/36.91
POLY-3 PERCENT (g)	2.4%	0%	0%	2.7%
TERMINAL (d)	1/29 (3%)	0/40 (0%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	729 (T)	---	---	601
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	23/900 (3%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Testes				
Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	1/42.11	2/47.23	1/41.50	1/36.72
POLY-3 PERCENT (g)	2.4%	4.2%	2.4%	2.7%
TERMINAL (d)	1/29 (3%)	2/40 (5%)	1/32 (3%)	0/19 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	729 (T)	662
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	7/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.574N	P=0.540	P=0.758	P=0.730
POLY 1.5	P=0.555N	P=0.523	P=0.758	P=0.744
POLY 6	P=0.597N	P=0.560	P=0.759	P=0.708
COCH-ARM / FISHERS	P=0.531N	P=0.500	P=0.753N	P=0.753N
MAX-ISO-POLY-3	P=0.655	P=0.324	P=0.495	P=0.463
HISTCONT SAME RTE	P=0.114	P=0.044*	P=0.302	P=0.281
HISTCONT ALL RTES	P=0.038*	P=0.010**	P=0.393	P=0.349
CURR VS HC SAME RTE	P=0.082			
CURR VS HC ALL RTES	P=0.348			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Thyroid Gland: Follicular Cell Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	2/50 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/42.11	0/46.47	2/41.80	0/35.47
POLY-3 PERCENT (g)	0%	0%	4.8%	0%
TERMINAL (d)	0/29 (0%)	0/40 (0%)	1/32 (3%)	0/18 (0%)
FIRST INCIDENCE	---	---	648	---
HC TUMORS SAME ROUTE	0/247 (0%)			
HC TUMORS ALL ROUTES	8/894 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.485	(e)	P=0.235	(e)
POLY 1.5	P=0.535	(e)	P=0.235	(e)
POLY 6	P=0.409	(e)	P=0.237	(e)
COCH-ARM / FISHERS	P=0.592	(e)	P=0.247	(e)
MAX-ISO-POLY-3	P=0.282	(e)	P=0.076	(e)
HISTCONT SAME RTE	P=0.224	(e)	P=0.023*	(e)
HISTCONT ALL RTES	P=0.372	(e)	P=0.024*	(e)
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.571			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Hemangioma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	3/50 (6%)	1/50 (2%)
POLY-3 RATE (b)	1/42.11	1/47.23	3/41.51	1/36.47
POLY-3 PERCENT (g)	2.4%	2.1%	7.2%	2.7%
TERMINAL (d)	1/29 (3%)	1/40 (3%)	2/32 (6%)	1/19 (5%)
FIRST INCIDENCE	729 (T)	729 (T)	726	729 (T)
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	12/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.452	P=0.734N	P=0.300	P=0.728
POLY 1.5	P=0.499	P=0.745N	P=0.301	P=0.743
POLY 6	P=0.387	P=0.720N	P=0.301	P=0.704
COCH-ARM / FISHERS	P=0.556	P=0.753N	P=0.309	P=0.753N
MAX-ISO-POLY-3	P=0.431	P=0.468N	P=0.151	P=0.461
HISTCONT SAME RTE	P=0.100	P=1.000	P=0.022*	P=0.417
HISTCONT ALL RTES	P=0.062	P=1.000	P=0.004**	P=1.000
CURR VS HC SAME RTE	P=0.322			
CURR VS HC ALL RTES	P=0.680			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	5/50 (10%)	5/50 (10%)	6/50 (12%)
POLY-3 RATE (b)	2/42.94	5/47.23	5/41.80	6/38.49
POLY-3 PERCENT (g)	4.7%	10.6%	12%	15.6%
TERMINAL (d)	0/29 (0%)	5/40 (13%)	4/32 (13%)	2/19 (11%)
FIRST INCIDENCE	596	729 (T)	648	470
HC TUMORS SAME ROUTE	21/250 (8%)			
HC TUMORS ALL ROUTES	90/900 (10%)			
STATISTICAL TESTS				
POLY 3	P=0.088	P=0.257	P=0.204	P=0.098
POLY 1.5	P=0.109	P=0.240	P=0.208	P=0.114
POLY 6	P=0.064	P=0.277	P=0.202	P=0.078
COCH-ARM / FISHERS	P=0.139	P=0.218	P=0.218	P=0.134
MAX-ISO-POLY-3	P=0.107	P=0.159	P=0.113	P=0.056
HISTCONT SAME RTE	P=0.204	P=0.488	P=0.393	P=0.199
HISTCONT ALL RTES	P=0.402	P=1.000	P=1.000	P=0.253
CURR VS HC SAME RTE	P=0.369			
CURR VS HC ALL RTES	P=0.175			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Hemangiosarcoma or Hemangioma				
TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	6/50 (12%)	8/50 (16%)	6/50 (12%)
POLY-3 RATE (b)	3/42.94	6/47.23	8/41.81	6/38.49
POLY-3 PERCENT (g)	7%	12.7%	19.1%	15.6%
TERMINAL (d)	1/29 (3%)	6/40 (15%)	6/32 (19%)	2/19 (11%)
FIRST INCIDENCE	596	729 (T)	648	470
HC TUMORS SAME ROUTE	23/250 (9%)			
HC TUMORS ALL ROUTES	102/900 (11%)			
STATISTICAL TESTS				
POLY 3	P=0.148	P=0.291	P=0.088	P=0.188
POLY 1.5	P=0.185	P=0.271	P=0.092	P=0.213
POLY 6	P=0.103	P=0.315	P=0.086	P=0.155
COCH-ARM / FISHERS	P=0.238	P=0.243	P=0.100	P=0.243
MAX-ISO-POLY-3	P=0.159	P=0.195	P=0.048*	P=0.120
HISTCONT SAME RTE	P=0.120	P=0.372	P=0.082	P=0.221
HISTCONT ALL RTES	P=0.237	P=1.000	P=0.093	P=0.372
CURR VS HC SAME RTE	P=0.555			
CURR VS HC ALL RTES	P=0.258			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Histiocytic Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	1/50 (2%)	1/50 (2%)
POLY-3 RATE (b)	2/42.11	1/47.23	1/41.80	1/36.96
POLY-3 PERCENT (g)	4.8%	2.1%	2.4%	2.7%
TERMINAL (d)	2/29 (7%)	1/40 (3%)	0/32 (0%)	0/19 (0%)
FIRST INCIDENCE	729 (T)	729 (T)	648	584
HC TUMORS SAME ROUTE	3/250 (1%)			
HC TUMORS ALL ROUTES	9/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.451N	P=0.460N	P=0.503N	P=0.545N
POLY 1.5	P=0.434N	P=0.477N	P=0.503N	P=0.525N
POLY 6	P=0.469N	P=0.440N	P=0.499N	P=0.576N
COCH-ARM / FISHERS	P=0.409N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.463N	P=0.259N	P=0.283N	P=0.329N
HISTCONT SAME RTE	P=0.282	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.180	P=1.000	P=1.000	P=0.455
CURR VS HC SAME RTE	P=0.083			
CURR VS HC ALL RTES	P=0.048*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	4/50 (8%)	0/50 (0%)
POLY-3 RATE (b)	2/42.37	2/47.60	4/41.50	0/36.47
POLY-3 PERCENT (g)	4.7%	4.2%	9.6%	0%
TERMINAL (d)	1/29 (3%)	0/40 (0%)	4/32 (13%)	0/19 (0%)
FIRST INCIDENCE	661	639	729 (T)	---
HC TUMORS SAME ROUTE	13/250 (5%)			
HC TUMORS ALL ROUTES	46/900 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.321N	P=0.651N	P=0.327	P=0.272N
POLY 1.5	P=0.279N	P=0.669N	P=0.330	P=0.255N
POLY 6	P=0.384N	P=0.629N	P=0.326	P=0.298N
COCH-ARM / FISHERS	P=0.232N	P=0.691N	P=0.339	P=0.247N
MAX-ISO-POLY-3	P=0.204N	P=0.454N	P=0.195	P=0.108N
HISTCONT SAME RTE	P=1.000	P=1.000	P=0.104	P=1.000
HISTCONT ALL RTES	P=1.000	P=1.000	P=0.140	P=1.000
CURR VS HC SAME RTE	P=0.802			
CURR VS HC ALL RTES	P=0.759			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	43/50 (86%)	41/50 (82%)	43/50 (86%)	35/50 (70%)
POLY-3 RATE (b)	43/47.67	41/48.56	43/47.87	35/42.98
POLY-3 PERCENT (g)	90.2%	84.4%	89.8%	81.4%
TERMINAL (d)	27/29 (93%)	36/40 (90%)	29/32 (91%)	18/19 (95%)
FIRST INCIDENCE	443	619	404	471
HC TUMORS SAME ROUTE	185/250 (74%)			
HC TUMORS ALL ROUTES	672/900 (75%)			
STATISTICAL TESTS				
POLY 3	P=0.176N	P=0.280N	P=0.621N	P=0.144N
POLY 1.5	P=0.083N	P=0.327N	P=0.622N	P=0.081N
POLY 6	P=0.388N	P=0.229N	P=0.601N	P=0.322N
COCH-ARM / FISHERS	P=0.029N*	P=0.393N	P=0.613N	P=0.045N*
MAX-ISO-POLY-3	P=0.159N	P=0.183N	P=0.472N	P=0.088N
HISTCONT SAME RTE	P=0.123	P=0.115	P=0.034*	P=0.259
HISTCONT ALL RTES	P=0.168	P=0.200	P=0.027*	P=0.451
CURR VS HC SAME RTE	P=0.033*			
CURR VS HC ALL RTES	P=0.054			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Malignant Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	37/50 (74%)	38/50 (76%)	42/50 (84%)	43/50 (86%)
POLY-3 RATE (b)	37/48.31	38/50.00	42/47.19	43/47.76
POLY-3 PERCENT (g)	76.6%	76%	89%	90%
TERMINAL (d)	19/29 (66%)	28/40 (70%)	28/32 (88%)	17/19 (90%)
FIRST INCIDENCE	443	521	429	425
HC TUMORS SAME ROUTE	154/250 (62%)			
HC TUMORS ALL ROUTES	556/900 (62%)			
STATISTICAL TESTS				
POLY 3	P=0.020*	P=0.567N	P=0.082	P=0.058
POLY 1.5	P=0.032*	P=0.573	P=0.103	P=0.075
POLY 6	P=0.011*	P=0.515N	P=0.074	P=0.041*
COCH-ARM / FISHERS	P=0.060	P=0.500	P=0.163	P=0.105
MAX-ISO-POLY-3	P=0.030*	P=0.471N	P=0.049*	P=0.032*
HISTCONT SAME RTE	P=0.008**	P=0.081	P=0.015*	P=0.013*
HISTCONT ALL RTES	P<0.001**	P=0.058	P<0.001**	P<0.001**
CURR VS HC SAME RTE	P=0.090			
CURR VS HC ALL RTES	P=0.080			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Males

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Malignant and Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	49/50 (98%)	49/50 (98%)	49/50 (98%)	48/50 (96%)
POLY-3 RATE (b)	49/49.33	49/50.00	49/49.48	48/48.88
POLY-3 PERCENT (g)	99.3%	98%	99%	98.2%
TERMINAL (d)	29/29 (100%)	39/40 (98%)	32/32 (100%)	19/19 (100%)
FIRST INCIDENCE	443	521	404	425
HC TUMORS SAME ROUTE	233/250 (93%)			
HC TUMORS ALL ROUTES	842/900 (94%)			
STATISTICAL TESTS				
POLY 3	P=0.541N	P=0.624N	P=0.927N	P=0.732N
POLY 1.5	P=0.432N	P=0.691N	P=0.835N	P=0.587N
POLY 6	P=0.729N	P=0.546N	P=1.000N	P=0.988N
COCH-ARM / FISHERS	P=0.351N	P=0.753N	P=0.753N	P=0.500N
MAX-ISO-POLY-3	P=0.443N	P=0.265N	P=0.395N	P=0.218N
HISTCONT SAME RTE	P=0.040*	P=0.091	P=0.054	P=0.083
HISTCONT ALL RTES	P=0.051	P=0.175	P=0.086	P=0.162
CURR VS HC SAME RTE	P=0.081			
CURR VS HC ALL RTES	P=0.142			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Adrenal Cortex Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	0/49 (0%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	1/43.32	0/38.61	0/42.78	0/37.17
POLY-3 PERCENT (g)	2.3%	0%	0%	0%
TERMINAL (d)	1/36 (3%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	731 (T)	---	---	---
HC TUMORS SAME ROUTE	1/249 (0%)			
HC TUMORS ALL ROUTES	5/895 (1%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Adrenal Medulla				
Pheochromocytoma: Benign, Complex, Malignant, NOS				
TUMOR RATES				
OVERALL (a)	2/50 (4%)	1/48 (2%)	0/50 (0%)	0/49 (0%)
POLY-3 RATE (b)	2/43.32	1/37.61	0/42.78	0/37.17
POLY-3 PERCENT (g)	4.6%	2.7%	0%	0%
TERMINAL (d)	2/36 (6%)	1/24 (4%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	731 (T)	731 (T)	---	---
HC TUMORS SAME ROUTE	6/249 (2%)			
HC TUMORS ALL ROUTES	16/896 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.101N	P=0.549N	P=0.240N	P=0.272N
POLY 1.5	P=0.101N	P=0.532N	P=0.237N	P=0.259N
POLY 6	P=0.101N	P=0.576N	P=0.246N	P=0.290N
COCH-ARM / FISHERS	P=0.101N	P=0.515N	P=0.247N	P=0.253N
MAX-ISO-POLY-3	P=0.123N	P=0.331N	P=0.078N	P=0.108N
HISTCONT SAME RTE	(h)	(h)	(h)	(h)
HISTCONT ALL RTES	P=1.000	P=1.000	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.584			
CURR VS HC ALL RTES	P=0.259			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Bone Marrow				
Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.32	0/39.12	0/42.78	0/38.11
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	9/899 (1%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Harderian Gland Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	5/50 (10%)	4/50 (8%)	1/50 (2%)
POLY-3 RATE (b)	1/43.32	5/39.61	4/42.78	1/38.11
POLY-3 PERCENT (g)	2.3%	12.6%	9.4%	2.6%
TERMINAL (d)	1/36 (3%)	4/25 (16%)	4/30 (13%)	1/24 (4%)
FIRST INCIDENCE	731 (T)	705	731 (T)	731 (T)
HC TUMORS SAME ROUTE	12/250 (5%)			
HC TUMORS ALL ROUTES	59/900 (7%)			
STATISTICAL TESTS				
POLY 3	P=0.480N	P=0.081	P=0.174	P=0.732
POLY 1.5	P=0.444N	P=0.091	P=0.178	P=0.744
POLY 6	P=0.527N	P=0.067	P=0.164	P=0.715
COCH-ARM / FISHERS	P=0.397N	P=0.102	P=0.181	P=0.753N
MAX-ISO-POLY-3	P=0.250	P=0.040*	P=0.082	P=0.465
HISTCONT SAME RTE	P=0.430	P=0.030*	P=0.113	P=1.000
HISTCONT ALL RTES	P=0.688	P=0.114	P=0.396	P=1.000
CURR VS HC SAME RTE	P=0.354			
CURR VS HC ALL RTES	P=0.218			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Harderian Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	3/50 (6%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	3/43.32	2/40.42	2/43.23	2/39.54
POLY-3 PERCENT (g)	6.9%	5%	4.6%	5.1%
TERMINAL (d)	3/36 (8%)	0/25 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	731 (T)	590	599	443
HC TUMORS SAME ROUTE	5/250 (2%)			
HC TUMORS ALL ROUTES	16/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.453N	P=0.532N	P=0.501N	P=0.542N
POLY 1.5	P=0.444N	P=0.515N	P=0.498N	P=0.524N
POLY 6	P=0.464N	P=0.558N	P=0.511N	P=0.565N
COCH-ARM / FISHERS	P=0.431N	P=0.500N	P=0.500N	P=0.500N
MAX-ISO-POLY-3	P=0.546N	P=0.356N	P=0.324N	P=0.366N
HISTCONT SAME RTE	P=0.150	P=0.281	P=0.310	P=0.273
HISTCONT ALL RTES	P=0.039*	P=0.167	P=0.187	P=0.161
CURR VS HC SAME RTE	P=0.079			
CURR VS HC ALL RTES	P=0.035*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Harderian Gland				
Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	7/50 (14%)	6/50 (12%)	3/50 (6%)
POLY-3 RATE (b)	4/43.32	7/40.52	6/43.23	3/39.54
POLY-3 PERCENT (g)	9.2%	17.3%	13.9%	7.6%
TERMINAL (d)	4/36 (11%)	4/25 (16%)	5/30 (17%)	1/24 (4%)
FIRST INCIDENCE	731 (T)	590	599	443
HC TUMORS SAME ROUTE	17/250 (7%)			
HC TUMORS ALL ROUTES	75/900 (8%)			
STATISTICAL TESTS				
POLY 3	P=0.374N	P=0.221	P=0.367	P=0.550N
POLY 1.5	P=0.349N	P=0.242	P=0.372	P=0.528N
POLY 6	P=0.409N	P=0.192	P=0.352	P=0.578N
COCH-ARM / FISHERS	P=0.316N	P=0.262	P=0.370	P=0.500N
MAX-ISO-POLY-3	P=0.356N	P=0.145	P=0.251	P=0.397N
HISTCONT SAME RTE	P=0.300	P=0.031*	P=0.080	P=1.000
HISTCONT ALL RTES	P=0.394	P=0.025*	P=0.135	P=1.000
CURR VS HC SAME RTE	P=0.751			
CURR VS HC ALL RTES	P=0.988			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Duodenum				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.32	0/39.50	0/42.78	0/38.11
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	2/900 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Ileum				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/43.77	1/39.99	1/43.39	3/38.43
POLY-3 PERCENT (g)	2.3%	2.5%	2.3%	7.8%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	2/24 (8%)
FIRST INCIDENCE	599	584	536	640
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	1/900 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.144	P=0.740	P=0.759	P=0.260
POLY 1.5	P=0.152	P=0.751	P=0.760N	P=0.279
POLY 6	P=0.135	P=0.723	P=0.752	P=0.238
COCH-ARM / FISHERS	P=0.163	P=0.753N	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.169	P=0.474	P=0.497	P=0.138
HISTCONT SAME RTE	P=0.008**	P=0.304	P=0.321	P=0.018*
HISTCONT ALL RTES	P<0.001**	P=0.039*	P=0.039*	P<0.001**
CURR VS HC SAME RTE	P=0.119			
CURR VS HC ALL RTES	P=0.004**			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Jejunum				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.32	0/39.50	0/42.78	0/38.11
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	1/900 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Site Unspecified				
Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/43.77	1/39.99	1/43.39	3/38.43
POLY-3 PERCENT (g)	2.3%	2.5%	2.3%	7.8%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	2/24 (8%)
FIRST INCIDENCE	599	584	536	640
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	4/900 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.144	P=0.740	P=0.759	P=0.260
POLY 1.5	P=0.152	P=0.751	P=0.760N	P=0.279
POLY 6	P=0.135	P=0.723	P=0.752	P=0.238
COCH-ARM / FISHERS	P=0.163	P=0.753N	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.169	P=0.474	P=0.497	P=0.138
HISTCONT SAME RTE	P=0.008**	P=0.304	P=0.321	P=0.018*
HISTCONT ALL RTES	P<0.001**	P=0.208	P=0.223	P<0.001**
CURR VS HC SAME RTE	P=0.119			
CURR VS HC ALL RTES	P=0.136			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Intestine Small: Site Unspecified				
Carcinoma or Adenoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	1/50 (2%)	2/50 (4%)	4/50 (8%)
POLY-3 RATE (b)	2/43.77	1/39.99	2/43.39	4/38.43
POLY-3 PERCENT (g)	4.6%	2.5%	4.6%	10.4%
TERMINAL (d)	1/36 (3%)	0/25 (0%)	1/30 (3%)	3/24 (13%)
FIRST INCIDENCE	599	584	536	640
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	8/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.141	P=0.531N	P=0.691	P=0.279
POLY 1.5	P=0.150	P=0.516N	P=0.693N	P=0.303
POLY 6	P=0.132	P=0.556N	P=0.681	P=0.251
COCH-ARM / FISHERS	P=0.164	P=0.500N	P=0.691N	P=0.339
MAX-ISO-POLY-3	P=0.161	P=0.314N	P=0.496	P=0.172
HISTCONT SAME RTE	P=0.005**	P=0.461	P=0.073	P=0.012*
HISTCONT ALL RTES	P<0.001**	P=0.433	P=0.023*	P<0.001**
CURR VS HC SAME RTE	P=0.057			
CURR VS HC ALL RTES	P=0.034*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Islets, Pancreatic Adenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/49 (2%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	1/43.98	1/39.58	2/43.03	0/38.11
POLY-3 PERCENT (g)	2.3%	2.5%	4.7%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	509	596	665	---
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	8/894 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.409N	P=0.737	P=0.492	P=0.528N
POLY 1.5	P=0.391N	P=0.747	P=0.497	P=0.516N
POLY 6	P=0.431N	P=0.721	P=0.481	P=0.543N
COCH-ARM / FISHERS	P=0.365N	P=0.747	P=0.500	P=0.500N
MAX-ISO-POLY-3	P=0.317N	P=0.470	P=0.276	P=0.193N
HISTCONT SAME RTE	P=0.316	P=0.299	P=0.044*	P=1.000
HISTCONT ALL RTES	P=0.377	P=0.430	P=0.023*	P=1.000
CURR VS HC SAME RTE	P=0.122			
CURR VS HC ALL RTES	P=0.433			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Kidney: Renal Tubule Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.32	0/39.50	0/42.78	1/38.11
POLY-3 PERCENT (g)	0%	0%	0%	2.6%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	---	---	---	731 (T)
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/897 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Kidney: Renal Tubule Carcinoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.32	0/39.50	0/42.78	0/38.11
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/897 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Kidney: Renal Tubule Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	1/50 (2%)
POLY-3 RATE (b)	0/43.32	0/39.50	0/42.78	1/38.11
POLY-3 PERCENT (g)	0%	0%	0%	2.6%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	1/24 (4%)
FIRST INCIDENCE	---	---	---	731 (T)
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/897 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hemangioma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	0/50 (0%)	2/50 (4%)
POLY-3 RATE (b)	0/43.32	1/39.50	0/42.78	2/38.11
POLY-3 PERCENT (g)	0%	2.5%	0%	5.3%
TERMINAL (d)	0/36 (0%)	1/25 (4%)	0/30 (0%)	2/24 (8%)
FIRST INCIDENCE	---	731 (T)	---	731 (T)
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	1/898 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.124	P=0.482	(e)	P=0.209
POLY 1.5	P=0.130	P=0.491	(e)	P=0.221
POLY 6	P=0.116	P=0.467	(e)	P=0.196
COCH-ARM / FISHERS	P=0.140	P=0.500	(e)	P=0.247
MAX-ISO-POLY-3	P=0.077	P=0.158	(e)	P=0.075
HISTCONT SAME RTE	P=0.023*	P=0.128	(e)	P=0.025*
HISTCONT ALL RTES	P<0.001**	P=0.036*	(e)	P<0.001**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.549			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	6/50 (12%)
POLY-3 RATE (b)	1/43.32	1/39.50	1/42.78	6/39.49
POLY-3 PERCENT (g)	2.3%	2.5%	2.3%	15.2%
TERMINAL (d)	1/36 (3%)	1/25 (4%)	1/30 (3%)	3/24 (13%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	508
HC TUMORS SAME ROUTE	5/250 (2%)			
HC TUMORS ALL ROUTES	14/898 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.007**	P=0.740	P=0.758	P=0.041*
POLY 1.5	P=0.008**	P=0.750	P=0.760	P=0.047*
POLY 6	P=0.007**	P=0.722	P=0.752	P=0.036*
COCH-ARM / FISHERS	P=0.009**	P=0.753N	P=0.753N	P=0.056
MAX-ISO-POLY-3	P=0.009**	P=0.474	P=0.496	P=0.021*
HISTCONT SAME RTE	P=0.015*	P=1.000	P=1.000	P=0.010**
HISTCONT ALL RTES	P<0.001**	P=1.000	P=1.000	P<0.001**
CURR VS HC SAME RTE	P=0.989			
CURR VS HC ALL RTES	P=0.788			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Adenoma				
TUMOR RATES				
OVERALL (a)	25/50 (50%)	21/50 (42%)	36/50 (72%)	29/50 (58%)
POLY-3 RATE (b)	25/45.19	21/42.88	36/46.41	29/42.02
POLY-3 PERCENT (g)	55.3%	49%	77.6%	69%
TERMINAL (d)	20/36 (56%)	13/25 (52%)	25/30 (83%)	19/24 (79%)
FIRST INCIDENCE	509	471	524	443
HC TUMORS SAME ROUTE	80/250 (32%)			
HC TUMORS ALL ROUTES	353/898 (39%)			
STATISTICAL TESTS				
POLY 3	P=0.026*	P=0.347N	P=0.015*	P=0.126
POLY 1.5	P=0.044*	P=0.304N	P=0.017*	P=0.180
POLY 6	P=0.014*	P=0.427N	P=0.012*	P=0.080
COCH-ARM / FISHERS	P=0.093	P=0.274N	P=0.020*	P=0.274
MAX-ISO-POLY-3	P=0.026*	P=0.276N	P=0.009**	P=0.092
HISTCONT SAME RTE	P=0.003**	P=0.031*	P=0.002**	P=0.004**
HISTCONT ALL RTES	P=0.016*	P=0.373	P=0.009**	P=0.050*
CURR VS HC SAME RTE	P=0.013*			
CURR VS HC ALL RTES	P=0.132			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma				
TUMOR RATES				
OVERALL (a)	8/50 (16%)	14/50 (28%)	12/50 (24%)	17/50 (34%)
POLY-3 RATE (b)	8/44.04	14/43.23	12/44.12	17/41.16
POLY-3 PERCENT (g)	18.2%	32.4%	27.2%	41.3%
TERMINAL (d)	6/36 (17%)	4/25 (16%)	8/30 (27%)	9/24 (38%)
FIRST INCIDENCE	611	478	611	415
HC TUMORS SAME ROUTE	36/250 (14%)			
HC TUMORS ALL ROUTES	144/898 (16%)			
STATISTICAL TESTS				
POLY 3	P=0.022*	P=0.097	P=0.223	P=0.015*
POLY 1.5	P=0.029*	P=0.106	P=0.229	P=0.020*
POLY 6	P=0.015*	P=0.084	P=0.207	P=0.010**
COCH-ARM / FISHERS	P=0.042*	P=0.114	P=0.227	P=0.032*
MAX-ISO-POLY-3	P=0.016*	P=0.062	P=0.155	P=0.010**
HISTCONT SAME RTE	P=0.007**	P=0.021*	P=0.053	P=0.008**
HISTCONT ALL RTES	P=0.010**	P=0.066	P=0.170	P=0.012*
CURR VS HC SAME RTE	P=0.767			
CURR VS HC ALL RTES	P=0.953			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	8/50 (16%)	14/50 (28%)	12/50 (24%)	17/50 (34%)
POLY-3 RATE (b)	8/44.04	14/43.23	12/44.12	17/41.16
POLY-3 PERCENT (g)	18.2%	32.4%	27.2%	41.3%
TERMINAL (d)	6/36 (17%)	4/25 (16%)	8/30 (27%)	9/24 (38%)
FIRST INCIDENCE	611	478	611	415
HC TUMORS SAME ROUTE	36/250 (14%)			
HC TUMORS ALL ROUTES	147/898 (16%)			
STATISTICAL TESTS				
POLY 3	P=0.022*	P=0.097	P=0.223	P=0.015*
POLY 1.5	P=0.029*	P=0.106	P=0.229	P=0.020*
POLY 6	P=0.015*	P=0.084	P=0.207	P=0.010**
COCH-ARM / FISHERS	P=0.042*	P=0.114	P=0.227	P=0.032*
MAX-ISO-POLY-3	P=0.016*	P=0.062	P=0.155	P=0.010**
HISTCONT SAME RTE	P=0.007**	P=0.021*	P=0.053	P=0.008**
HISTCONT ALL RTES	P=0.014*	P=0.077	P=0.187	P=0.015*
CURR VS HC SAME RTE	P=0.767			
CURR VS HC ALL RTES	P=0.999			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma or Hepatocellular Adenoma				
TUMOR RATES				
OVERALL (a)	28/50 (56%)	30/50 (60%)	37/50 (74%)	38/50 (76%)
POLY-3 RATE (b)	28/45.50	30/45.90	37/46.64	38/45.05
POLY-3 PERCENT (g)	61.5%	65.4%	79.3%	84.4%
TERMINAL (d)	22/36 (61%)	14/25 (56%)	25/30 (83%)	21/24 (88%)
FIRST INCIDENCE	509	471	524	415
HC TUMORS SAME ROUTE	105/250 (42%)			
HC TUMORS ALL ROUTES	420/898 (47%)			
STATISTICAL TESTS				
POLY 3	P=0.003**	P=0.434	P=0.041*	P=0.009**
POLY 1.5	P=0.005**	P=0.438	P=0.044*	P=0.013*
POLY 6	P=0.002**	P=0.418	P=0.036*	P=0.006**
COCH-ARM / FISHERS	P=0.012*	P=0.420	P=0.046*	P=0.028*
MAX-ISO-POLY-3	P=0.005**	P=0.348	P=0.025*	P=0.004**
HISTCONT SAME RTE	P=0.002**	P=0.018*	P=0.004**	P=0.004**
HISTCONT ALL RTES	P=0.006**	P=0.169	P=0.026*	P=0.014*
CURR VS HC SAME RTE	P=0.068			
CURR VS HC ALL RTES	P=0.199			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma				
TUMOR RATES				
OVERALL (a)	28/50 (56%)	30/50 (60%)	37/50 (74%)	38/50 (76%)
POLY-3 RATE (b)	28/45.50	30/45.90	37/46.64	38/45.05
POLY-3 PERCENT (g)	61.5%	65.4%	79.3%	84.4%
TERMINAL (d)	22/36 (61%)	14/25 (56%)	25/30 (83%)	21/24 (88%)
FIRST INCIDENCE	509	471	524	415
HC TUMORS SAME ROUTE	105/250 (42%)			
HC TUMORS ALL ROUTES	420/898 (47%)			
STATISTICAL TESTS				
POLY 3	P=0.003**	P=0.434	P=0.041*	P=0.009**
POLY 1.5	P=0.005**	P=0.438	P=0.044*	P=0.013*
POLY 6	P=0.002**	P=0.418	P=0.036*	P=0.006**
COCH-ARM / FISHERS	P=0.012*	P=0.420	P=0.046*	P=0.028*
MAX-ISO-POLY-3	P=0.005**	P=0.348	P=0.025*	P=0.004**
HISTCONT SAME RTE	P=0.002**	P=0.018*	P=0.004**	P=0.004**
HISTCONT ALL RTES	P=0.006**	P=0.169	P=0.026*	P=0.014*
CURR VS HC SAME RTE	P=0.068			
CURR VS HC ALL RTES	P=0.199			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Liver				
Hepatocholangiocarcinoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	1/50 (2%)	1/50 (2%)	2/50 (4%)
POLY-3 RATE (b)	0/43.32	1/39.96	1/43.08	2/39.32
POLY-3 PERCENT (g)	0%	2.5%	2.3%	5.1%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	596	648	508
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	0/898 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.135	P=0.484	P=0.499	P=0.216
POLY 1.5	P=0.143	P=0.492	P=0.500	P=0.225
POLY 6	P=0.127	P=0.471	P=0.494	P=0.206
COCH-ARM / FISHERS	P=0.153	P=0.500	P=0.500	P=0.247
MAX-ISO-POLY-3	P=0.121	P=0.158	P=0.158	P=0.075
HISTCONT SAME RTE	P=0.006**	P=0.127	P=0.125	P=0.024*
HISTCONT ALL RTES	P<0.001**	P=0.004**	P=0.003**	P<0.001**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=1.000			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Lung				
Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	3/50 (6%)	4/50 (8%)	2/50 (4%)	2/49 (4%)
POLY-3 RATE (b)	3/43.32	4/40.88	2/42.78	2/37.83
POLY-3 PERCENT (g)	6.9%	9.8%	4.7%	5.3%
TERMINAL (d)	3/36 (8%)	1/25 (4%)	2/30 (7%)	1/24 (4%)
FIRST INCIDENCE	731 (T)	478	731 (T)	508
HC TUMORS SAME ROUTE	13/249 (5%)			
HC TUMORS ALL ROUTES	51/899 (6%)			
STATISTICAL TESTS				
POLY 3	P=0.369N	P=0.468	P=0.506N	P=0.561N
POLY 1.5	P=0.352N	P=0.486	P=0.501N	P=0.539N
POLY 6	P=0.391N	P=0.438	P=0.520N	P=0.589N
COCH-ARM / FISHERS	P=0.327N	P=0.500	P=0.500N	P=0.510N
MAX-ISO-POLY-3	P=0.461N	P=0.323	P=0.329N	P=0.386N
HISTCONT SAME RTE	P=0.720	P=0.287	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.765	P=0.259	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.826			
CURR VS HC ALL RTES	P=0.882			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Lung				
Alveolar/Bronchiolar Carcinoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	2/50 (4%)	7/50 (14%)	5/49 (10%)
POLY-3 RATE (b)	1/43.32	2/40.60	7/43.63	5/39.40
POLY-3 PERCENT (g)	2.3%	4.9%	16.1%	12.7%
TERMINAL (d)	1/36 (3%)	0/25 (0%)	6/30 (20%)	1/24 (4%)
FIRST INCIDENCE	731 (T)	558	392	502
HC TUMORS SAME ROUTE	12/249 (5%)			
HC TUMORS ALL ROUTES	37/899 (4%)			
STATISTICAL TESTS				
POLY 3	P=0.038*	P=0.477	P=0.030*	P=0.080
POLY 1.5	P=0.042*	P=0.489	P=0.031*	P=0.087
POLY 6	P=0.033*	P=0.458	P=0.027*	P=0.073
COCH-ARM / FISHERS	P=0.052	P=0.500	P=0.030*	P=0.098
MAX-ISO-POLY-3	P=0.047*	P=0.268	P=0.012*	P=0.039*
HISTCONT SAME RTE	P=0.063	P=1.000	P=0.041*	P=0.122
HISTCONT ALL RTES	P=0.005**	P=1.000	P=0.002**	P=0.028*
CURR VS HC SAME RTE	P=0.430			
CURR VS HC ALL RTES	P=0.491			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Lung				
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma				
TUMOR RATES				
OVERALL (a)	4/50 (8%)	5/50 (10%)	9/50 (18%)	7/49 (14%)
POLY-3 RATE (b)	4/43.32	5/41.42	9/43.63	7/40.07
POLY-3 PERCENT (g)	9.2%	12.1%	20.6%	17.5%
TERMINAL (d)	4/36 (11%)	1/25 (4%)	8/30 (27%)	2/24 (8%)
FIRST INCIDENCE	731 (T)	478	392	502
HC TUMORS SAME ROUTE	24/249 (10%)			
HC TUMORS ALL ROUTES	86/899 (10%)			
STATISTICAL TESTS				
POLY 3	P=0.141	P=0.472	P=0.115	P=0.216
POLY 1.5	P=0.153	P=0.488	P=0.119	P=0.229
POLY 6	P=0.130	P=0.443	P=0.104	P=0.200
COCH-ARM / FISHERS	P=0.172	P=0.500	P=0.117	P=0.251
MAX-ISO-POLY-3	P=0.174	P=0.339	P=0.067	P=0.141
HISTCONT SAME RTE	P=0.098	P=1.000	P=0.070	P=0.174
HISTCONT ALL RTES	P=0.034*	P=0.487	P=0.022*	P=0.107
CURR VS HC SAME RTE	P=0.748			
CURR VS HC ALL RTES	P=0.772			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Mammary Gland Carcinoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	2/50 (4%)	1/50 (2%)
POLY-3 RATE (b)	1/43.32	1/39.50	2/42.78	1/38.11
POLY-3 PERCENT (g)	2.3%	2.5%	4.7%	2.6%
TERMINAL (d)	1/36 (3%)	1/25 (4%)	2/30 (7%)	1/24 (4%)
FIRST INCIDENCE	731 (T)	731 (T)	731 (T)	731 (T)
HC TUMORS SAME ROUTE	10/250 (4%)			
HC TUMORS ALL ROUTES	16/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.540	P=0.740	P=0.496	P=0.732
POLY 1.5	P=0.561	P=0.750	P=0.500	P=0.744
POLY 6	P=0.514	P=0.722	P=0.485	P=0.715
COCH-ARM / FISHERS	P=0.591	P=0.753N	P=0.500	P=0.753N
MAX-ISO-POLY-3	P=0.577	P=0.474	P=0.278	P=0.465
HISTCONT SAME RTE	P=1.000	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.420	P=1.000	P=0.218	P=1.000
CURR VS HC SAME RTE	P=0.504			
CURR VS HC ALL RTES	P=0.888			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Ovary				
Cystadenoma				
TUMOR RATES				
OVERALL (a)	1/50 (2%)	3/49 (6%)	1/49 (2%)	1/49 (2%)
POLY-3 RATE (b)	1/43.32	3/39.27	1/42.32	1/37.85
POLY-3 PERCENT (g)	2.3%	7.6%	2.4%	2.6%
TERMINAL (d)	1/36 (3%)	2/25 (8%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	731 (T)	673	668	502
HC TUMORS SAME ROUTE	11/247 (5%)			
HC TUMORS ALL ROUTES	42/889 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.488N	P=0.270	P=0.756	P=0.730
POLY 1.5	P=0.472N	P=0.284	P=0.757	P=0.741
POLY 6	P=0.509N	P=0.249	P=0.751	P=0.716
COCH-ARM / FISHERS	P=0.450N	P=0.301	P=0.747	P=0.747
MAX-ISO-POLY-3	P=0.481N	P=0.141	P=0.493	P=0.463
HISTCONT SAME RTE	P=1.000	P=0.282	P=1.000	P=1.000
HISTCONT ALL RTES	P=1.000	P=0.360	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.411			
CURR VS HC ALL RTES	P=0.397			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Ovary				
Hemangioma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/49 (0%)	2/49 (4%)	0/49 (0%)
POLY-3 RATE (b)	0/43.32	0/39.05	2/42.08	0/37.17
POLY-3 PERCENT (g)	0%	0%	4.8%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	2/30 (7%)	0/24 (0%)
FIRST INCIDENCE	---	---	731 (T)	---
HC TUMORS SAME ROUTE	0/247 (0%)			
HC TUMORS ALL ROUTES	1/889 (0%)			
STATISTICAL TESTS				
POLY 3	P=0.523	(e)	P=0.230	(e)
POLY 1.5	P=0.552	(e)	P=0.233	(e)
POLY 6	P=0.490	(e)	P=0.224	(e)
COCH-ARM / FISHERS	P=0.592	(e)	P=0.242	(e)
MAX-ISO-POLY-3	P=0.275	(e)	P=0.074	(e)
HISTCONT SAME RTE	P=0.206	(e)	P=0.021*	(e)
HISTCONT ALL RTES	P=0.079	(e)	P<0.001**	(e)
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.563			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Pituitary Gland: Pars Distalis or Unspecified Site				
Adenoma				
TUMOR RATES				
OVERALL (a)	8/50 (16%)	5/50 (10%)	8/48 (17%)	4/47 (9%)
POLY-3 RATE (b)	8/43.32	5/40.46	8/40.78	4/37.50
POLY-3 PERCENT (g)	18.5%	12.4%	19.6%	10.7%
TERMINAL (d)	8/36 (22%)	3/25 (12%)	8/28 (29%)	2/24 (8%)
FIRST INCIDENCE	731 (T)	584	731 (T)	556
HC TUMORS SAME ROUTE	29/242 (12%)			
HC TUMORS ALL ROUTES	64/883 (7%)			
STATISTICAL TESTS				
POLY 3	P=0.277N	P=0.319N	P=0.557	P=0.252N
POLY 1.5	P=0.263N	P=0.296N	P=0.569	P=0.233N
POLY 6	P=0.294N	P=0.359N	P=0.526	P=0.275N
COCH-ARM / FISHERS	P=0.241N	P=0.277N	P=0.572	P=0.210N
MAX-ISO-POLY-3	P=0.289N	P=0.228N	P=0.446	P=0.176N
HISTCONT SAME RTE	P=0.622	P=1.000	P=0.178	P=1.000
HISTCONT ALL RTES	P=0.131	P=0.264	P=0.018*	P=0.404
CURR VS HC SAME RTE	P=0.414			
CURR VS HC ALL RTES	P=0.021*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Pituitary Gland: Pars Distalis or Unspecified Site				
Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	8/50 (16%)	5/50 (10%)	9/48 (19%)	4/47 (9%)
POLY-3 RATE (b)	8/43.32	5/40.46	9/41.01	4/37.50
POLY-3 PERCENT (g)	18.5%	12.4%	22%	10.7%
TERMINAL (d)	8/36 (22%)	3/25 (12%)	8/28 (29%)	2/24 (8%)
FIRST INCIDENCE	731 (T)	584	670	556
HC TUMORS SAME ROUTE	30/242 (12%)			
HC TUMORS ALL ROUTES	65/883 (7%)			
STATISTICAL TESTS				
POLY 3	P=0.298N	P=0.319N	P=0.450	P=0.252N
POLY 1.5	P=0.282N	P=0.296N	P=0.461	P=0.233N
POLY 6	P=0.316N	P=0.359N	P=0.422	P=0.275N
COCH-ARM / FISHERS	P=0.258N	P=0.277N	P=0.463	P=0.210N
MAX-ISO-POLY-3	P=0.294N	P=0.228N	P=0.347	P=0.176N
HISTCONT SAME RTE	P=0.565	P=1.000	P=0.108	P=1.000
HISTCONT ALL RTES	P=0.108	P=0.276	P=0.008**	P=0.416
CURR VS HC SAME RTE	P=0.459			
CURR VS HC ALL RTES	P=0.025*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	4/50 (8%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	2/43.75	4/40.64	4/43.30	6/39.09
POLY-3 PERCENT (g)	4.6%	9.8%	9.2%	15.4%
TERMINAL (d)	1/36 (3%)	1/25 (4%)	2/30 (7%)	3/24 (13%)
FIRST INCIDENCE	605	563	653	592
HC TUMORS SAME ROUTE	15/250 (6%)			
HC TUMORS ALL ROUTES	41/900 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.080	P=0.303	P=0.332	P=0.098
POLY 1.5	P=0.091	P=0.320	P=0.337	P=0.112
POLY 6	P=0.069	P=0.277	P=0.320	P=0.084
COCH-ARM / FISHERS	P=0.109	P=0.339	P=0.339	P=0.134
MAX-ISO-POLY-3	P=0.091	P=0.183	P=0.197	P=0.057
HISTCONT SAME RTE	P=0.138	P=0.383	P=0.416	P=0.135
HISTCONT ALL RTES	P=0.009**	P=0.168	P=0.191	P=0.014*
CURR VS HC SAME RTE	P=0.651			
CURR VS HC ALL RTES	P=0.889			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	4/50 (8%)	4/50 (8%)	6/50 (12%)
POLY-3 RATE (b)	2/43.75	4/40.64	4/43.30	6/39.09
POLY-3 PERCENT (g)	4.6%	9.8%	9.2%	15.4%
TERMINAL (d)	1/36 (3%)	1/25 (4%)	2/30 (7%)	3/24 (13%)
FIRST INCIDENCE	605	563	653	592
HC TUMORS SAME ROUTE	15/250 (6%)			
HC TUMORS ALL ROUTES	41/900 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.080	P=0.303	P=0.332	P=0.098
POLY 1.5	P=0.091	P=0.320	P=0.337	P=0.112
POLY 6	P=0.069	P=0.277	P=0.320	P=0.084
COCH-ARM / FISHERS	P=0.109	P=0.339	P=0.339	P=0.134
MAX-ISO-POLY-3	P=0.091	P=0.183	P=0.197	P=0.057
HISTCONT SAME RTE	P=0.138	P=0.383	P=0.416	P=0.135
HISTCONT ALL RTES	P=0.009**	P=0.168	P=0.191	P=0.014*
CURR VS HC SAME RTE	P=0.651			
CURR VS HC ALL RTES	P=0.889			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Fibrous Histiocytoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	3/50 (6%)
POLY-3 RATE (b)	0/43.32	2/40.21	2/43.02	3/38.11
POLY-3 PERCENT (g)	0%	5%	4.7%	7.9%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	1/30 (3%)	3/24 (13%)
FIRST INCIDENCE	---	563	668	731 (T)
HC TUMORS SAME ROUTE	1/250 (0%)			
HC TUMORS ALL ROUTES	5/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.083	P=0.221	P=0.235	P=0.097
POLY 1.5	P=0.093	P=0.229	P=0.237	P=0.106
POLY 6	P=0.071	P=0.208	P=0.230	P=0.087
COCH-ARM / FISHERS	P=0.108	P=0.247	P=0.247	P=0.121
MAX-ISO-POLY-3	P=0.079	P=0.075	P=0.076	P=0.037*
HISTCONT SAME RTE	P=0.006**	P=0.045*	P=0.044*	P=0.018*
HISTCONT ALL RTES	P<0.001**	P=0.025*	P=0.027*	P<0.001**
CURR VS HC SAME RTE	P=0.480			
CURR VS HC ALL RTES	P=0.610			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Skin				
Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	1/50 (2%)	1/50 (2%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	1/43.32	1/39.93	1/42.78	3/39.09
POLY-3 PERCENT (g)	2.3%	2.5%	2.3%	7.7%
TERMINAL (d)	1/36 (3%)	0/25 (0%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	731 (T)	606	731 (T)	592
HC TUMORS SAME ROUTE	14/250 (6%)			
HC TUMORS ALL ROUTES	23/900 (3%)			
STATISTICAL TESTS				
POLY 3	P=0.148	P=0.743	P=0.758	P=0.269
POLY 1.5	P=0.154	P=0.752	P=0.760	P=0.284
POLY 6	P=0.142	P=0.727	P=0.752	P=0.253
COCH-ARM / FISHERS	P=0.163	P=0.753N	P=0.753N	P=0.309
MAX-ISO-POLY-3	P=0.173	P=0.477	P=0.496	P=0.141
HISTCONT SAME RTE	P=0.575	P=1.000	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.263	P=1.000	P=1.000	P=0.155
CURR VS HC SAME RTE	P=0.360			
CURR VS HC ALL RTES	P=0.841			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Spleen				
Hemangiosarcoma				
TUMOR RATES				
OVERALL (a)	3/50 (6%)	3/49 (6%)	1/50 (2%)	1/49 (2%)
POLY-3 RATE (b)	3/43.32	3/39.86	1/42.78	1/37.76
POLY-3 PERCENT (g)	6.9%	7.5%	2.3%	2.7%
TERMINAL (d)	3/36 (8%)	2/25 (8%)	1/30 (3%)	1/24 (4%)
FIRST INCIDENCE	731 (T)	471	731 (T)	731 (T)
HC TUMORS SAME ROUTE	7/249 (3%)			
HC TUMORS ALL ROUTES	14/890 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.188N	P=0.624	P=0.309N	P=0.356N
POLY 1.5	P=0.180N	P=0.640	P=0.306N	P=0.337N
POLY 6	P=0.199N	P=0.595	P=0.320N	P=0.379N
COCH-ARM / FISHERS	P=0.168N	P=0.651	P=0.309N	P=0.316N
MAX-ISO-POLY-3	P=0.289N	P=0.458	P=0.158N	P=0.204N
HISTCONT SAME RTE	P=0.573	P=0.062	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.284	P=0.004**	P=1.000	P=1.000
CURR VS HC SAME RTE	P=0.233			
CURR VS HC ALL RTES	P=0.020*			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Stomach, Forestomach				
Squamous Cell Papilloma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	3/50 (6%)	1/50 (2%)	0/50 (0%)
POLY-3 RATE (b)	0/43.32	3/39.50	1/43.07	0/38.11
POLY-3 PERCENT (g)	0%	7.6%	2.3%	0%
TERMINAL (d)	0/36 (0%)	3/25 (12%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	731 (T)	653	---
HC TUMORS SAME ROUTE	2/250 (1%)			
HC TUMORS ALL ROUTES	15/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.420N	P=0.102	P=0.499	(e)
POLY 1.5	P=0.396N	P=0.110	P=0.500	(e)
POLY 6	P=0.452N	P=0.091	P=0.494	(e)
COCH-ARM / FISHERS	P=0.366N	P=0.121	P=0.500	(e)
MAX-ISO-POLY-3	P=0.257N	P=0.037*	P=0.158	(e)
HISTCONT SAME RTE	P=0.387	P=0.023*	P=0.492	(e)
HISTCONT ALL RTES	P=0.504	P=0.010**	P=1.000	(e)
CURR VS HC SAME RTE	P=0.486			
CURR VS HC ALL RTES	P=0.400			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Thyroid Gland: Follicular Cell Carcinoma or Adenoma				
TUMOR RATES				
OVERALL (a)	0/50 (0%)	0/50 (0%)	0/50 (0%)	0/50 (0%)
POLY-3 RATE (b)	0/43.32	0/39.50	0/42.78	0/38.11
POLY-3 PERCENT (g)	0%	0%	0%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	0/30 (0%)	0/24 (0%)
FIRST INCIDENCE	---	---	---	---
HC TUMORS SAME ROUTE	2/249 (1%)			
HC TUMORS ALL ROUTES	4/892 (0%)			
STATISTICAL TESTS				
POLY 3	(n)	(n)	(n)	(n)
POLY 1.5	(n)	(n)	(n)	(n)
POLY 6	(n)	(n)	(n)	(n)
COCH-ARM / FISHERS	(n)	(n)	(n)	(n)
MAX-ISO-POLY-3	(n)	(n)	(n)	(n)
HISTCONT SAME RTE	(n)	(n)	(n)	(n)
HISTCONT ALL RTES	(n)	(n)	(n)	(n)
CURR VS HC SAME RTE	(n)			
CURR VS HC ALL RTES	(n)			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
Uterus				
Polyp Stromal				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	1/50 (2%)	3/50 (6%)
POLY-3 RATE (b)	2/43.32	2/39.94	1/42.78	3/39.05
POLY-3 PERCENT (g)	4.6%	5%	2.3%	7.7%
TERMINAL (d)	2/36 (6%)	1/25 (4%)	1/30 (3%)	0/24 (0%)
FIRST INCIDENCE	731 (T)	603	731 (T)	626
HC TUMORS SAME ROUTE	4/250 (2%)			
HC TUMORS ALL ROUTES	20/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.376	P=0.665	P=0.504N	P=0.453
POLY 1.5	P=0.387	P=0.680	P=0.500N	P=0.472
POLY 6	P=0.364	P=0.640	P=0.515N	P=0.432
COCH-ARM / FISHERS	P=0.404	P=0.691N	P=0.500N	P=0.500
MAX-ISO-POLY-3	P=0.371	P=0.467	P=0.285N	P=0.292
HISTCONT SAME RTE	P=0.043*	P=0.189	P=1.000	P=0.049*
HISTCONT ALL RTES	P=0.077	P=0.296	P=1.000	P=0.056
CURR VS HC SAME RTE	P=0.244			
CURR VS HC ALL RTES	P=0.407			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Hemangioma				
TUMOR RATES	#	#	#	#
OVERALL (a)	0/50 (0%)	2/50 (4%)	2/50 (4%)	2/50 (4%)
POLY-3 RATE (b)	0/43.32	2/39.61	2/42.78	2/38.11
POLY-3 PERCENT (g)	0%	5.1%	4.7%	5.3%
TERMINAL (d)	0/36 (0%)	1/25 (4%)	2/30 (7%)	2/24 (8%)
FIRST INCIDENCE	---	705	731 (T)	731 (T)
HC TUMORS SAME ROUTE	0/250 (0%)			
HC TUMORS ALL ROUTES	5/900 (1%)			
STATISTICAL TESTS				
POLY 3	P=0.195	P=0.217	P=0.234	P=0.209
POLY 1.5	P=0.214	P=0.227	P=0.237	P=0.221
POLY 6	P=0.173	P=0.203	P=0.227	P=0.196
COCH-ARM / FISHERS	P=0.242	P=0.247	P=0.247	P=0.247
MAX-ISO-POLY-3	P=0.192	P=0.075	P=0.076	P=0.075
HISTCONT SAME RTE	P=0.012*	P=0.024*	P=0.021*	P=0.025*
HISTCONT ALL RTES	P<0.001**	P=0.004**	P=0.003**	P=0.004**
CURR VS HC SAME RTE	P=1.000			
CURR VS HC ALL RTES	P=0.587			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Hemangiosarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	4/50 (8%)	4/50 (8%)	9/50 (18%)
POLY-3 RATE (b)	4/43.32	4/40.24	4/43.28	9/40.05
POLY-3 PERCENT (g)	9.2%	9.9%	9.2%	22.5%
TERMINAL (d)	4/36 (11%)	3/25 (12%)	2/30 (7%)	5/24 (21%)
FIRST INCIDENCE	731 (T)	471	620	508
HC TUMORS SAME ROUTE	17/250 (7%)			
HC TUMORS ALL ROUTES	46/900 (5%)			
STATISTICAL TESTS				
POLY 3	P=0.044*	P=0.603	P=0.643	P=0.084
POLY 1.5	P=0.047*	P=0.624	P=0.641N	P=0.096
POLY 6	P=0.040*	P=0.565	P=0.633	P=0.072
COCH-ARM / FISHERS	P=0.055	P=0.643N	P=0.643N	P=0.117
MAX-ISO-POLY-3	P=0.060	P=0.457	P=0.499	P=0.052
HISTCONT SAME RTE	P=0.009**	P=0.373	P=0.482	P=0.009**
HISTCONT ALL RTES	P<0.001**	P=0.211	P=0.246	P<0.001**
CURR VS HC SAME RTE	P=0.745			
CURR VS HC ALL RTES	P=0.351			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Hemangiosarcoma or Hemangioma				
TUMOR RATES	#	#	#	#
OVERALL (a)	4/50 (8%)	6/50 (12%)	6/50 (12%)	11/50 (22%)
POLY-3 RATE (b)	4/43.32	6/40.34	6/43.28	11/40.05
POLY-3 PERCENT (g)	9.2%	14.9%	13.9%	27.5%
TERMINAL (d)	4/36 (11%)	4/25 (16%)	4/30 (13%)	7/24 (29%)
FIRST INCIDENCE	731 (T)	471	620	508
HC TUMORS SAME ROUTE	17/250 (7%)			
HC TUMORS ALL ROUTES	51/900 (6%)			
STATISTICAL TESTS				
POLY 3	P=0.018*	P=0.324	P=0.368	P=0.027*
POLY 1.5	P=0.021*	P=0.348	P=0.372	P=0.034*
POLY 6	P=0.015*	P=0.285	P=0.354	P=0.022*
COCH-ARM / FISHERS	P=0.027*	P=0.370	P=0.370	P=0.045*
MAX-ISO-POLY-3	P=0.021*	P=0.222	P=0.251	P=0.017*
HISTCONT SAME RTE	P=0.003**	P=0.040*	P=0.049*	P=0.006**
HISTCONT ALL RTES	P<0.001**	P=0.024*	P=0.031*	P<0.001**
CURR VS HC SAME RTE	P=0.745			
CURR VS HC ALL RTES	P=0.465			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Histiocytic Sarcoma				
TUMOR RATES	#	#	#	#
OVERALL (a)	2/50 (4%)	2/50 (4%)	2/50 (4%)	0/50 (0%)
POLY-3 RATE (b)	2/44.57	2/40.42	2/42.78	0/38.11
POLY-3 PERCENT (g)	4.5%	5%	4.7%	0%
TERMINAL (d)	0/36 (0%)	0/25 (0%)	2/30 (7%)	0/24 (0%)
FIRST INCIDENCE	440	529	731 (T)	---
HC TUMORS SAME ROUTE	7/250 (3%)			
HC TUMORS ALL ROUTES	21/900 (2%)			
STATISTICAL TESTS				
POLY 3	P=0.199N	P=0.659	P=0.679	P=0.274N
POLY 1.5	P=0.184N	P=0.676	P=0.687	P=0.258N
POLY 6	P=0.220N	P=0.632	P=0.664	P=0.293N
COCH-ARM / FISHERS	P=0.163N	P=0.691N	P=0.691N	P=0.247N
MAX-ISO-POLY-3	P=0.236N	P=0.461	P=0.483	P=0.110N
HISTCONT SAME RTE	P=0.757	P=0.406	P=0.468	P=1.000
HISTCONT ALL RTES	P=0.645	P=0.259	P=0.291	P=1.000
CURR VS HC SAME RTE	P=0.656			
CURR VS HC ALL RTES	P=0.457			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, NOS, or Undifferentiated Cell Type				
TUMOR RATES	#	#	#	#
OVERALL (a)	14/50 (28%)	20/50 (40%)	13/50 (26%)	11/50 (22%)
POLY-3 RATE (b)	14/44.52	20/42.57	13/43.18	11/39.21
POLY-3 PERCENT (g)	31.5%	47%	30.1%	28.1%
TERMINAL (d)	11/36 (31%)	11/25 (44%)	11/30 (37%)	8/24 (33%)
FIRST INCIDENCE	509	563	668	440
HC TUMORS SAME ROUTE	69/250 (28%)			
HC TUMORS ALL ROUTES	211/900 (23%)			
STATISTICAL TESTS				
POLY 3	P=0.231N	P=0.098	P=0.538N	P=0.460N
POLY 1.5	P=0.184N	P=0.119	P=0.515N	P=0.399N
POLY 6	P=0.303N	P=0.075	P=0.583N	P=0.539N
COCH-ARM / FISHERS	P=0.134N	P=0.146	P=0.500N	P=0.322N
MAX-ISO-POLY-3	P=0.252N	P=0.068	P=0.445N	P=0.373N
HISTCONT SAME RTE	P=0.582	P=0.047*	P=1.000	P=1.000
HISTCONT ALL RTES	P=0.361	P=0.010**	P=0.347	P=0.459
CURR VS HC SAME RTE	P=0.959			
CURR VS HC ALL RTES	P=0.424			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	32/50 (64%)	34/50 (68%)	38/50 (76%)	34/50 (68%)
POLY-3 RATE (b)	32/45.19	34/45.90	38/46.41	34/43.70
POLY-3 PERCENT (g)	70.8%	74.1%	81.9%	77.8%
TERMINAL (d)	27/36 (75%)	19/25 (76%)	27/30 (90%)	21/24 (88%)
FIRST INCIDENCE	509	471	524	443
HC TUMORS SAME ROUTE	126/250 (50%)			
HC TUMORS ALL ROUTES	499/900 (55%)			
STATISTICAL TESTS				
POLY 3	P=0.210	P=0.452	P=0.142	P=0.292
POLY 1.5	P=0.264	P=0.448	P=0.144	P=0.341
POLY 6	P=0.165	P=0.438	P=0.129	P=0.246
COCH-ARM / FISHERS	P=0.359	P=0.417	P=0.138	P=0.417
MAX-ISO-POLY-3	P=0.236	P=0.357	P=0.094	P=0.215
HISTCONT SAME RTE	P=0.007**	P=0.010**	P=0.004**	P=0.008**
HISTCONT ALL RTES	P=0.021*	P=0.103	P=0.023*	P=0.062
CURR VS HC SAME RTE	P=0.040*			
CURR VS HC ALL RTES	P=0.163			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Malignant Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	33/50 (66%)	39/50 (78%)	36/50 (72%)	41/50 (82%)
POLY-3 RATE (b)	33/47.73	39/48.22	36/48.06	41/48.99
POLY-3 PERCENT (g)	69.2%	80.9%	74.9%	83.7%
TERMINAL (d)	23/36 (64%)	17/25 (68%)	21/30 (70%)	18/24 (75%)
FIRST INCIDENCE	440	471	392	413
HC TUMORS SAME ROUTE	144/250 (58%)			
HC TUMORS ALL ROUTES	475/900 (53%)			
STATISTICAL TESTS				
POLY 3	P=0.091	P=0.132	P=0.342	P=0.069
POLY 1.5	P=0.083	P=0.135	P=0.349	P=0.063
POLY 6	P=0.100	P=0.130	P=0.320	P=0.077
COCH-ARM / FISHERS	P=0.073	P=0.133	P=0.333	P=0.055
MAX-ISO-POLY-3	P=0.065	P=0.089	P=0.263	P=0.044*
HISTCONT SAME RTE	P=0.012*	P=0.017*	P=0.047*	P=0.011*
HISTCONT ALL RTES	P=0.006**	P=0.019*	P=0.055	P=0.010**
CURR VS HC SAME RTE	P=0.338			
CURR VS HC ALL RTES	P=0.080			

STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1)
TERMINAL SACRIFICE AT 105 WEEKS

Females

DOSE	Control	6.25 ppm	12.5 ppm	25 ppm
All Organs				
Malignant and Benign Tumors				
TUMOR RATES	#	#	#	#
OVERALL (a)	45/50 (90%)	46/50 (92%)	47/50 (94%)	47/50 (94%)
POLY-3 RATE (b)	45/47.73	46/48.94	47/49.54	47/49.12
POLY-3 PERCENT (g)	94.3%	94%	94.9%	95.7%
TERMINAL (d)	35/36 (97%)	23/25 (92%)	29/30 (97%)	23/24 (96%)
FIRST INCIDENCE	440	471	392	413
HC TUMORS SAME ROUTE	204/250 (82%)			
HC TUMORS ALL ROUTES	706/900 (78%)			
STATISTICAL TESTS				
POLY 3	P=0.434	P=0.660N	P=0.637	P=0.566
POLY 1.5	P=0.363	P=0.639	P=0.533	P=0.474
POLY 6	P=0.537	P=0.630N	P=0.689N	P=0.682
COCH-ARM / FISHERS	P=0.278	P=0.500	P=0.357	P=0.357
MAX-ISO-POLY-3	P=0.566	P=0.471N	P=0.443	P=0.365
HISTCONT SAME RTE	P=0.007**	P=0.012*	P=0.009**	P=0.008**
HISTCONT ALL RTES	P=0.022*	P=0.070	P=0.055	P=0.046*
CURR VS HC SAME RTE	P=0.065			
CURR VS HC ALL RTES	P=0.031*			

LEGEND

(a)	Number of tumor-bearing animals/number of animals examined at site.
(b)	Number of tumor-bearing animals/Poly-3 number
(d)	Observed incidence at terminal kill.
(e)	Value of statistic cannot be computed.
(f)	Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group.
(g)	Poly-3 adjusted lifetime tumor incidence.
(h)	Historical Controls statistic is not calculated when the HC Poly-3 rate is higher than the Poly-3 rates for all dose groups.
(n)	No statistics are calculated if all dose groups have fewer than two tumors.
(I)	Interim sacrifice
(T)	Terminal sacrifice
#	Tumor rates based on numbers of animals necropsied.
*	To the right of any statistical result, indicates significance at (P<=0.05).
**	To the right of any statistical result, indicates significance at (P<=0.01).
N	Indicates a negative trend for all tests
	The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***